The Diagnostic Dermatology Imaging Devices Market was valued at USD 4.93 Billion in 2024, and is projected to reach USD 8.39 Billion by 2030, rising at a CAGR of 9.40%. The growing prevalence of skin disorders, rising awareness about skin cancers, and the growing demand for non-invasive diagnostic procedures are the factors affecting the market's growth. There is a significant rise in the number of skin cancer cases globally, which drives the need for advanced solutions to facilitate better cancer care. For instance, in February 2025, Canfield Scientific introduced the new D2 Digital Dermatoscope, which has a high-resolution display, and its design enhances ease of use and elevates the user experience. It enables consistent, standardized imaging for accurate documentation and precise diagnostics.
The increasing prevalence of skin disorders and skin cancers significantly drives the growth of the diagnostic dermatology imaging devices market. Skin cancer, including melanoma and non-melanoma types such as basal cell carcinoma and squamous cell carcinoma, continues to rise globally due to factors like prolonged UV exposure, aging populations, and enhanced awareness and screening efforts. According to the American Academy of Dermatology, skin cancer is most prevalent in the U.S.; approximately 9,500 people are diagnosed with skin cancer daily, and over 1 million individuals are currently suffering from melanoma.
Furthermore, the Global Cancer Observatory (GLOBOCAN) reports that the number of skin melanoma cases is expected to increase to 599,565. Skin cancers are predominantly found in women under the age of 50, but they occur significantly more frequently in men over the age of 50. This discrepancy can be attributed to differences in recreational and occupational UV exposure. Estimates suggest that around 1 in 27 men and 1 in 40 women are expected to suffer from melanoma.
The growing awareness of early disease diagnosis has emerged as a critical driver in healthcare, particularly in fields like dermatology, where early intervention can significantly improve patient outcomes. Increased public education, widespread use of digital health platforms, and a greater understanding of skin cancer risks empowered individuals to seek medical attention sooner, creating a demand for accurate, non-invasive diagnostic tools. This trend is particularly significant for detecting conditions such as melanoma, where early identification can be lifesaving. Consequently, dermatology clinics, hospitals, and even primary care providers increasingly adopt advanced imaging technologies to address the market demand.
This directly influences technological innovation and strategic activity within the companies operating in this market. For instance, in May 2023, Orlucent, Inc. received FDA Breakthrough Device Designation for its Skin Fluorescence Imaging System, which provides a non-invasive molecular analysis of moles. This approval marks a significant advancement in the market for diagnostic dermatology imaging devices. The handheld, non-invasive device uses a topically applied fluorescent peptide to detect αvβ3 integrin, which indicates early melanoma development. By offering molecular-level imaging and analysis of moles, the mSFI system allows clinicians to evaluate the biological tissue remodeling activity associated with atypical moles, thereby enabling the early detection of melanoma without requiring invasive procedures.
Additionally, the growing demand for non-invasive diagnostic approaches is fueling market expansion. Both patients and clinicians increasingly favor methods that eliminate the risks, discomfort, and downtime linked with conventional biopsies. This trend is particularly prominent in dermatology-especially skin cancer diagnosis-where early detection is vital. Techniques like optical coherence tomography (OCT), reflectance confocal microscopy (RCM), and dermoscopy deliver detailed skin lesion imaging, supporting accurate assessment and ongoing monitoring.
Technological advancements have played a pivotal role in this transition. Devices like DermaSensor, which received FDA clearance in January 2024, utilize AI-powered spectroscopy to non-invasively assess skin lesions for potential malignancy. In clinical studies, DermaSensor demonstrated a sensitivity of 97% in detecting various skin cancers, including melanoma, basal cell carcinoma, and squamous cell carcinoma. Such innovations not only improve diagnostic accuracy but also reduce reliance on subjective clinical assessments, enabling more consistent and efficient evaluations. The further emergence of technologically advanced devices, such as hyperspectral dermatoscopes, offers a promising approach for non-invasive skin evaluation. These devices capture a broad range of wavelengths with high precision, identifying and characterizing various skin conditions. Preliminary results suggest that hyperspectral imaging can enhance diagnostic accuracy, providing a new platform for research and clinical applications in dermatology.
The increasing prevalence of skin disorders and skin cancers significantly drives the growth of the diagnostic dermatology imaging devices market. Skin cancer, including melanoma and non-melanoma types such as basal cell carcinoma and squamous cell carcinoma, continues to rise globally due to factors like prolonged UV exposure, aging populations, and enhanced awareness and screening efforts. According to the American Academy of Dermatology, skin cancer is most prevalent in the U.S.; approximately 9,500 people are diagnosed with skin cancer daily, and over 1 million individuals are currently suffering from melanoma.
Furthermore, the Global Cancer Observatory (GLOBOCAN) reports that the number of skin melanoma cases is expected to increase to 599,565. Skin cancers are predominantly found in women under the age of 50, but they occur significantly more frequently in men over the age of 50. This discrepancy can be attributed to differences in recreational and occupational UV exposure. Estimates suggest that around 1 in 27 men and 1 in 40 women are expected to suffer from melanoma.
The growing awareness of early disease diagnosis has emerged as a critical driver in healthcare, particularly in fields like dermatology, where early intervention can significantly improve patient outcomes. Increased public education, widespread use of digital health platforms, and a greater understanding of skin cancer risks empowered individuals to seek medical attention sooner, creating a demand for accurate, non-invasive diagnostic tools. This trend is particularly significant for detecting conditions such as melanoma, where early identification can be lifesaving. Consequently, dermatology clinics, hospitals, and even primary care providers increasingly adopt advanced imaging technologies to address the market demand.
This directly influences technological innovation and strategic activity within the companies operating in this market. For instance, in May 2023, Orlucent, Inc. received FDA Breakthrough Device Designation for its Skin Fluorescence Imaging System, which provides a non-invasive molecular analysis of moles. This approval marks a significant advancement in the market for diagnostic dermatology imaging devices. The handheld, non-invasive device uses a topically applied fluorescent peptide to detect αvβ3 integrin, which indicates early melanoma development. By offering molecular-level imaging and analysis of moles, the mSFI system allows clinicians to evaluate the biological tissue remodeling activity associated with atypical moles, thereby enabling the early detection of melanoma without requiring invasive procedures.
Additionally, the growing demand for non-invasive diagnostic approaches is fueling market expansion. Both patients and clinicians increasingly favor methods that eliminate the risks, discomfort, and downtime linked with conventional biopsies. This trend is particularly prominent in dermatology-especially skin cancer diagnosis-where early detection is vital. Techniques like optical coherence tomography (OCT), reflectance confocal microscopy (RCM), and dermoscopy deliver detailed skin lesion imaging, supporting accurate assessment and ongoing monitoring.
Technological advancements have played a pivotal role in this transition. Devices like DermaSensor, which received FDA clearance in January 2024, utilize AI-powered spectroscopy to non-invasively assess skin lesions for potential malignancy. In clinical studies, DermaSensor demonstrated a sensitivity of 97% in detecting various skin cancers, including melanoma, basal cell carcinoma, and squamous cell carcinoma. Such innovations not only improve diagnostic accuracy but also reduce reliance on subjective clinical assessments, enabling more consistent and efficient evaluations. The further emergence of technologically advanced devices, such as hyperspectral dermatoscopes, offers a promising approach for non-invasive skin evaluation. These devices capture a broad range of wavelengths with high precision, identifying and characterizing various skin conditions. Preliminary results suggest that hyperspectral imaging can enhance diagnostic accuracy, providing a new platform for research and clinical applications in dermatology.
Global Diagnostic Dermatology Imaging Devices Market Report: Segmentation
This report forecasts country-level revenue growth at global, regional, and country level and analyzes the latest industry trends and opportunities in each sub-segment from 2018 to 2030. For this study, the analyst has segmented the global diagnostic dermatology imaging devices market report based on the modality, application, end use, and region:Modality Outlook (Revenue, USD Million, 2018-2030)
- Advanced Diagnostic Imaging Devices
- Surface Visualization Devices
- Biopsy Devices
- Molecular Diagnostic Devices & Platforms
Application Outlook (Revenue, USD Million 2018-2030)
- Skin Cancer
- Inflammatory & Autoimmune Skin Diseases
- Infectious Skin Conditions
- Wound & Ulcer Assessment
End Use Outlook (Revenue, USD Million 2018-2030)
- Hospitals
- Dermatology Clinics/Centers
- Cancer Centers/Oncology Clinics
- Others
Regional Outlook (Revenue, USD Million, 2018-2030)
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Diagnostic Dermatology Imaging Devices Market Variables, Trends & Scope
Chapter 4. Diagnostic Dermatology Imaging Devices Market: Modality Estimates & Trend Analysis
Chapter 5. Diagnostic Dermatology Imaging Devices Market: Application Estimates & Trend Analysis
Chapter 6. Diagnostic Dermatology Imaging Devices Market: End Use Estimates & Trend Analysis
Chapter 7. Diagnostic Dermatology Imaging Devices Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this Diagnostic Dermatology Imaging Devices market report include:- Canfield Scientific
- Caliber Imaging & Diagnostics
- Michelson Diagnostics (MDL)
- SciBase AB
- DermaSensor Inc.
- Damae Medical
- Apollo Medical Optics
- Enspectra Health, Inc.
- Cortex Technology
- Dermavision Solutions
- Pixience
- Adamo srl. (Horus)
- Dermus Ltd.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 185 |
| Published | April 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 4.93 Billion |
| Forecasted Market Value ( USD | $ 8.39 Billion |
| Compound Annual Growth Rate | 9.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 14 |
